A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)

Exclusion Criteria

• •1. Patients with known primary brain tumors, leptomeningeal disease or untreated brain metastases. Subjects with previously treated brain metastases may participate provided the brain metastases are stable
• •2. Previous treatment with vesicular stomatitis virus (VSV)-based agents
• •3. Concomitant medication or condition considered a high risk for complications from injection